ICON Public (NASDAQ:ICLR) Trading 5.8% Higher

ICON Public Limited (NASDAQ:ICLRGet Free Report) shares traded up 5.8% during trading on Thursday . The company traded as high as $332.52 and last traded at $327.59. 354,070 shares were traded during mid-day trading, a decline of 35% from the average session volume of 543,155 shares. The stock had previously closed at $309.52.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. TD Cowen lifted their price objective on shares of ICON Public from $343.00 to $349.00 and gave the company a “buy” rating in a research report on Friday, April 26th. Robert W. Baird boosted their target price on shares of ICON Public from $362.00 to $363.00 and gave the company an “outperform” rating in a research report on Friday, April 26th. Mizuho restated a “buy” rating and issued a $346.00 target price on shares of ICON Public in a research report on Thursday, April 4th. Truist Financial boosted their target price on shares of ICON Public from $357.00 to $367.00 and gave the company a “buy” rating in a research report on Friday, February 23rd. Finally, Barclays lifted their price target on shares of ICON Public from $325.00 to $355.00 and gave the company an “overweight” rating in a report on Friday, February 23rd. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat.com, ICON Public currently has an average rating of “Moderate Buy” and an average price target of $339.44.

View Our Latest Stock Report on ICLR

ICON Public Stock Performance

The stock’s 50 day moving average price is $314.10 and its 200 day moving average price is $294.43. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.21 and a current ratio of 1.21. The company has a market capitalization of $26.59 billion, a P/E ratio of 39.65, a price-to-earnings-growth ratio of 1.49 and a beta of 1.18.

ICON Public (NASDAQ:ICLRGet Free Report) last released its earnings results on Wednesday, April 24th. The medical research company reported $3.38 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.30 by $0.08. ICON Public had a net margin of 8.30% and a return on equity of 11.70%. The company had revenue of $2.09 billion for the quarter, compared to the consensus estimate of $2.09 billion. As a group, equities analysts expect that ICON Public Limited will post 14.41 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. SkyView Investment Advisors LLC acquired a new position in ICON Public during the first quarter worth $1,021,000. Motco raised its holdings in ICON Public by 1.5% during the first quarter. Motco now owns 3,882 shares of the medical research company’s stock worth $1,304,000 after buying an additional 59 shares during the last quarter. First National Bank of Hutchinson raised its holdings in ICON Public by 5.7% during the first quarter. First National Bank of Hutchinson now owns 1,135 shares of the medical research company’s stock worth $381,000 after buying an additional 61 shares during the last quarter. Whittier Trust Co. of Nevada Inc. raised its holdings in ICON Public by 410.8% during the first quarter. Whittier Trust Co. of Nevada Inc. now owns 189 shares of the medical research company’s stock worth $63,000 after buying an additional 152 shares during the last quarter. Finally, Whittier Trust Co. raised its holdings in ICON Public by 21.9% during the first quarter. Whittier Trust Co. now owns 3,295 shares of the medical research company’s stock worth $1,107,000 after buying an additional 593 shares during the last quarter. Institutional investors and hedge funds own 95.61% of the company’s stock.

About ICON Public

(Get Free Report)

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

Featured Articles

Receive News & Ratings for ICON Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICON Public and related companies with MarketBeat.com's FREE daily email newsletter.